arrow
M

M. Dror Michaelson

Harvard Medical School
H指数:65
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) vs. dose escalated radiation therapy and enhanced ADT with orteronel for men with high-risk prostate cancer (NRG/RTOG 1115)

剂量 escalated 放射治疗和标准雄激素剥夺治疗(ADT)与剂量 escalated 放射治疗和奥曲酮增强雄激素剥夺治疗的高危前列腺癌患者的III期试验(NRG/RTOG 1115)

2025-07-230
PRE
Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)

更新后的双抗体药物偶联物(DAD)I期临床试验疗效概况:Sacituzumab govitecan(SG)联合Enfortumab vedotin(EV)在转移性尿路上皮癌(mUC)中≥二线治疗的疗效情况

2024-09-010
PRE
Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines
2024-02-0123
PRE
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel plus Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
2024-02-010
PRE
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

Beztifan治疗晚期实体瘤的I期LITESPARK-001研究: 在透明细胞肾细胞癌队列中延长41个月的随访

2024-01-017
PRE
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma

双抗体药物偶联物 (DAD) I期试验: sacituzumab govitecan加enfortumab vedotin治疗转移性尿路上皮癌

2024-01-0123
OA
Kidney Cancer, Version 3.2022
2022-01-01352
OA
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors
2021-11-0112
PRE
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes (vol 26, pg 1041, 2020)
2020-09-074
OAAI
Kidney Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines
2020-09-01175
OA